Anti- Esophageal Cancer Active Immunity Induced by FasL/B7-1 Genes Modified Tumor Cells
Dept. of Cardio-Thoracic Surg., First Affiliated Hosp. of Suzhou Univ., SuzhouDOI: 10.1109/ICBBE.2008.103 Conference: Bioinformatics and Biomedical Engineering, 2008. ICBBE 2008. The 2nd International Conference on
Source: IEEE Xplore
To study the activation of CTLs against esophageal cancer cells induced by FasL/B7-1 (FB-11)genes modified tumor cells, and to explore whether co-expression of FasL and B7-1 in Eca-109 tumor cells could initiate an synergistic antitumor effect. FasL and B7-1 genes were transfected into human Eca-109 Eca-109 cancer cells with adenovirus vectors. The positive clones were selected by G418. FasL and B7-1 were detected by Flow cytometry and RT-PCR . The abdominal infiltrating lymphocytes and sensitized spleen cells were obtained from the mice who were immunized with Eca-109/FB-11 or wild type Eca-109 cells intraperitoneally, and the cytotoxicity of these CTLs against tumor cells was determined by MTT assay. Flow cytometry and RT-PCR showed that FasL and B7-1 were highly expressed. FasL+/B7-1+ Eca-109 cells (Eca-109/FB-11) were inoculated subcutaneously in the dorsal skin of C57BL/6 mice and then they decreased their tumorigenicity greatly (z=2.15-46.10, p<0.01). The Eca-109/FB-11 cell-sensitized mice obtained the protective immune activity against the rechallenge of wild type Eca-109 cells (z=2.06-44.30, p<0.05). It was showed that the cytotoxicity of CTLs induced by Eca-109/FB-11 cells against Eca-109 was significantly higher than that of CTLs activated by wild-type Eca-109 cells (84.1plusmn2.4% vs 30.5plusmn2.3%, p<0.05). The results suggest that the FasL and B7-1 can effectively promote the activity of CTLs against esophageal cancer cells.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.